Incorporating the AUA/SUO Guideline on Advanced Prostate Cancer into Practice

Incorporating the AUA/SUO Guideline on Advanced Prostate Cancer into Practice

CME Available: https://auau.auanet.org/node/39292
Guideline Pocket Guide: https://auau.auanet.org/node/40925

Incorporating the AUA/SUO Guideline on Advanced Prostate Cancer into Practice (2023) is an exciting new educational initiative featuring a series of three interactive, case-based, live virtual courses conducted in English, Spanish and Portuguese. For each session, a Moderator will engage three other subject matter experts in an interactive, interview-style presentation and discussion.

To assist in clinical decision-making, evidence-based guideline statements were developed to provide a rational basis for evidence-based treatment. This guideline covers advanced prostate cancer, including disease stages that range from prostate-specific antigen (PSA) recurrence after exhaustion of local treatment options to widespread metastatic disease. Based on the findings from the latest AUA needs assessment in advanced prostate cancer, the AUA has developed a virtual course to update urologists on this newest clinical guideline for the management of advanced prostate cancer.

Each activity will be recorded and feature subject matter experts from around the world. The webcasts will be made available on AUAUniversity and AUA’s YouTube channel for on‐demand viewing for up to one year. Additionally, the audio of the virtual course presented in English will be released as an episode on AUA’s very popular podcast.

Learners will also be provided with links to access additional resources including the AUA’s clinical guidelines discussed during the virtual courses and associated patient resources.

After participating in this educational activity, participants will be able to:
1. Cite recommendations within the newly amended AUA/SUO Advanced Prostate Cancer Guideline.
2. Assess the impact of newly approved agents on the management of men with Advanced Prostate Cancer.
3. Define M0 CRPC and the treatment options.
4. Identify clinically meaningful endpoints in clinical trials of patients with M0 CRPC.
5. Describe gaps in the knowledge for treatment and sequencing of agents in the management of CRPC.
6. Discuss treatment intensification in mHSPC.
7. Discuss challenges in incorporating AUA/SUO Advanced Prostate Cancer Guideline and management of advanced mHSPC and CRPC into community practice.


ACKNOWLEDGEMENTS
This educational series is supported by independent educational grants from:
Astellas and Pfizer, Inc.
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Lantheus Medical Imaging
Merck & Co., Inc.
Pfizer, Inc.